Abstract:After the outbreak of coronavirus disease 2019 (COVID-19), its long-term sequelae after recovery has become the wide-ranging concern. Sequelae symptoms and complications, including, but not limited to, chronic fatigue, lung fibrosis, anxiety, depression, cognitive impairment, and venous thromboembolism, have emerged in some patients after hospital stay.1Davies A. et al.Lancet Respir Med. 2021; 9: 1467-1478Abstract Full Text Full Text PDF PubMed Scopus (44) Google Scholar,2Weng J. et al.Lancet Gastroenterol Hepatol. 2021; 6: 344-346Abstract Full Text Full Text PDF PubMed Scopus (45) Google Scholar However, little is currently known on the underlying mechanisms of these chronic health sequelae. Zhang et al3Zhang F. et al.Gastroenterology. 2022; 162: 548-561.e4Abstract Full Text Full Text PDF PubMed Scopus (58) Google Scholar reported that severe or critical patients with COVID-19 are characterized by impaired capacity of gut microbiome for short-chain fatty acid (SCFA), l-isoleucine biosynthesis, and enhanced capacity for urea production for their gut microbiome. To our knowledge, this is the first longitudinal cohort study of hospital survivors with COVID-19 so far to describe the dynamic gut microbiome functionality within 30 days after discharge. By metagenomic analysis, they found Bray-Curtis dissimilarity of microbial pathways in patients with COVID-19 with severe/critical illness was significantly higher than in individuals without COVID-19. In particular, SCFA biosynthesis of commensal bacteria served as the energy sources of host cells. Its impairment thus could contribute to the symptoms of fatigue and muscle weakness. Besides, they were also conscious of dietary factors of patients over the course of hospitalization, which were substantiated to be excluded. This study has comprehensively clarified how gut microbiome functionality modulates the outcome of patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) during hospitalization and beyond 1 month after discharge. Even though Zhang et al3Zhang F. et al.Gastroenterology. 2022; 162: 548-561.e4Abstract Full Text Full Text PDF PubMed Scopus (58) Google Scholar claimed the limitations of their dietary records before disease onset and mechanistic studies between SARS-CoV-2 infection and the gut immune system, this study is also lacking in plasma measurements to solidify its conclusion. All levels of plasma multiomics profiles were previously determined in 139 patients with COVID-19 from their serial blood draws collected during the first week of infection after diagnosis.4Su Y. et al.Cell. 2020; 183: 1479-1495Abstract Full Text Full Text PDF PubMed Scopus (263) Google Scholar They identified the upregulation of chemokine (C-C motif) ligand 7 (CCL7), interleukin (IL) 10, and IL6 (that barely misses significance between moderate and severe disease with P = .056). Keratin-19 (KRT19) involved in the organization of muscle fibers is upregulated in all comparisons and may be a marker of tissue damage between moderate and severe COVID-19 cases. Several inflammation-associated proteins, including CCL7 and IL6, are anticorrelated with many plasma lipids. For healthy donors or mildly infected patients, these lipid levels drop precipitously. Therefore, the mentioned plasma measurements were insufficient for the perspective of inflammatory reaction. More proinflammatory cytokines (eg, chemokine [C-X-C motif] ligand 6) and proteins associated with immune cell activation (eg, cluster of differentiation 244 and 40) as high contributing factors should be determined in patients with COVID-19 and their controls. In addition, relationships between plasma analytes, clinical measures, and disease severity also deserve to be explored. For example, blood urea nitrogen (in hospitalized patients) has many connections with amino acid metabolism, suggesting amino acid catabolism in advanced COVID-19.4Su Y. et al.Cell. 2020; 183: 1479-1495Abstract Full Text Full Text PDF PubMed Scopus (263) Google Scholar The discoveries reported by Zhang et al3Zhang F. et al.Gastroenterology. 2022; 162: 548-561.e4Abstract Full Text Full Text PDF PubMed Scopus (58) Google Scholar highlight the effects that gut microbial metabolism can have on COVID-19 severity and demonstrate that microbiota functional capabilities are critical for the long-term recovery from SARS-CoV-2 infections. A highly diverse microbial community has an intrinsic capacity to act as a protective barrier against virus invasion and pathobiont expansion in the circulatory system. Gut metabolites or signaling molecules, such as SCFA, l-isoleucine, and urea production, play an important role in these inherent protective functions of the microbiota. The functional properties of native microbiota and its molecules mediating virus colonization should be the focus of further work, with the potential to harness them for new and improved therapies. Prolonged Impairment of Short-Chain Fatty Acid and L-Isoleucine Biosynthesis in Gut Microbiome in Patients With COVID-19GastroenterologyVol. 162Issue 2PreviewGut microbiome of patients with coronavirus disease 2019 displayed impaired capacity for short chain fatty acids and L-isoleucine biosynthesis. Further studies are needed to understand how impaired gut microbial functions are involved in disease outcome. Full-Text PDF ReplyGastroenterologyVol. 163Issue 1PreviewWe would like to thank Zhang et al1 for their interest in our article and for highlighting the importance of mechanistic studies to shed light on functional properties of native microbiota and its molecules mediating virus colonization. Full-Text PDF

Prolonged Impairment of Short-Chain Fatty Acid and L-Isoleucine Biosynthesis in Gut Microbiome in Patients With COVID-19

Gut Microbiota Improves Prognostic Prediction in Critically Ill COVID-19 Patients Alongside Immunological and Hematological Indicators

The Faecal Metabolome in COVID-19 Patients is Altered and Associated with Clinical Features and Gut Microbes

Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19

Gut Microbiome Metabolism Drives the Resolution of Patients with Coronavirus Disease 2019

Alterations in Gut Microbiota of Patients With COVID-19 During Time of Hospitalization

Alterations of the Gut Microbiota in Patients with Coronavirus Disease 2019 or H1N1 Influenza.

Gut Mycobiota Alterations in Patients with COVID-19 and H1N1 Infections and Their Associations with Clinical Features

Alterations in Fecal Fungal Microbiome of Patients With COVID-19 During Time of Hospitalization until Discharge

Gut microbiota dynamics in a prospective cohort of patients with post-acute COVID-19 syndrome

Gut mycobiota alterations in patients with COVID-19 and H1N1 and associations with immune and gastrointestinal symptoms

Fecal multi-omics analysis reveals diverse molecular alterations of gut ecosystem in COVID-19 patients

Gut Microbiome Alterations in COVID-19

Microbiome Profiling Using Shotgun Metagenomic Sequencing Identified Unique Microorganisms in COVID-19 Patients With Altered Gut Microbiota

Gut microbiota from patients with COVID-19 cause alterations in mice that resemble post-COVID symptoms

Signatures of disease outcome severity in the intestinal fungal and bacterial microbiome of COVID-19 patients

SARS-CoV-2 infection is associated with intestinal permeability, systemic inflammation, and microbial dysbiosis in hospitalized patients

Depicting SARS-CoV-2 Faecal Viral Activity in Association with Gut Microbiota Composition in Patients with COVID-19

Altered gut microbiome in convalescent patients with coronavirus disease 2019

Impact of SARS-CoV-2 infection on respiratory and gut microbiome stability: a metagenomic investigation in long-term-hospitalized COVID-19 patients

Persistent intestinal dysbiosis after SARS-CoV-2 infection in Brazilian patients